20 May , 2025 By : Debdeep Gupta
Gland Pharma's stock is trading higher by 2.24% at Rs 1,517.10 in today's session. The stock is a part of the NIFTY MIDCAP 150 index.
Financial Performance
A review of Gland Pharma's financial performance reveals the following trends:
Quarterly Performance:
* December 2023: Revenue was Rs 1,097.86 Cr, with a net profit of Rs 276.81 Cr and EPS of Rs 16.81.
* March 2024: Revenue increased to Rs 1,174.83 Cr, net profit was Rs 321.41 Cr, and EPS stood at Rs 19.51.
* June 2024: Revenue decreased to Rs 1,012.02 Cr, net profit was Rs 222.92 Cr, and EPS was Rs 13.53.
* September 2024: Revenue slightly increased to Rs 1,062.99 Cr, net profit was Rs 281.71 Cr, and EPS was Rs 17.10.
* December 2024: Revenue was Rs 1,010.78 Cr, with a net profit of Rs 295.12 Cr and EPS of Rs 17.91.
Annual Performance:
* 2020: Revenue was Rs 2,633.24 Cr, net profit was Rs 772.86 Cr, and EPS was Rs 49.88.
* 2021: Revenue increased to Rs 3,462.88 Cr, net profit was Rs 997.01 Cr, and EPS was Rs 63.07.
* 2022: Revenue further increased to Rs 4,400.71 Cr, net profit was Rs 1,212.16 Cr, and EPS was Rs 73.84.
* 2023: Revenue decreased to Rs 3,616.53 Cr, net profit was Rs 775.83 Cr, and EPS was Rs 47.12.
* 2024: Revenue increased to Rs 4,167.43 Cr, net profit was Rs 1,043.33 Cr, and EPS was Rs 63.35.
The company's Book Value Per Share (BVPS) has also shown consistent growth, from Rs 235.32 in 2020 to Rs 546.13 in 2024. The Return on Equity (ROE) has fluctuated, with a value of 11.59 in 2024. Gland Pharma has maintained a Debt to Equity ratio of 0.00 from 2020 to 2024, indicating a debt-free status.
Cash Flow:
The cash flow analysis indicates the following:
* 2020: Net Cash Flow was -Rs 66 Cr.
* 2021: Net Cash Flow increased to Rs 322 Cr.
* 2022: Net Cash Flow was -Rs 180 Cr.
* 2023: Net Cash Flow significantly increased to Rs 1,594 Cr.
* 2024: Net Cash Flow was -Rs 1,789 Cr.
Balance Sheet:
The balance sheet data shows:
* 2020: Total Assets were Rs 4,086 Cr.
* 2021: Total Assets increased to Rs 6,496 Cr.
* 2022: Total Assets further increased to Rs 7,834 Cr.
* 2023: Total Assets increased to Rs 8,773 Cr.
* 2024: Total Assets increased to Rs 9,541 Cr.
Financial Ratios:
* Basic EPS (Rs.): Increased from Rs 49.88 in March 2020 to Rs 63.35 in March 2024.
* Net Profit Margin (%): Fluctuated, with a value of 25.03 in March 2024.
* Return on Networth / Equity (%): Was 11.59 in March 2024.
* Debt to Equity (x): Consistently at 0.00 from March 2020 to March 2024.
Overall, the sentiment analysis for Gland Pharma is neutral, according to Source's analysis as of 2025-05-14. The stock continues to be actively traded in today's session.
0 Comment